[go: up one dir, main page]

US20080008682A1 - Modulators of toll-like receptor 7 - Google Patents

Modulators of toll-like receptor 7 Download PDF

Info

Publication number
US20080008682A1
US20080008682A1 US11/825,377 US82537707A US2008008682A1 US 20080008682 A1 US20080008682 A1 US 20080008682A1 US 82537707 A US82537707 A US 82537707A US 2008008682 A1 US2008008682 A1 US 2008008682A1
Authority
US
United States
Prior art keywords
substituted
alkylene
group
alkyl
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/825,377
Other languages
English (en)
Inventor
Lee Chong
Manoj Desai
Brian Gallagher
Michael Graupe
Randall Halcomb
Hong Yang
Jennifer Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to US11/825,377 priority Critical patent/US20080008682A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHONG, LEE S., DESAI, MANOJ C., GRAUPE, MICHAEL, HALCOMB, RANDALL L., YANG, HONG, ZHANG, JENNIFER R., GALLAGHER, BRIAN
Publication of US20080008682A1 publication Critical patent/US20080008682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This application relates generally to compounds and pharmaceutical compositions which selectively activates toll-like receptor 7 (TLR7), and methods of making and using them.
  • TLR7 toll-like receptor 7
  • the innate immune system provides the body with a first line defense against invading pathogens.
  • an invading pathogen is recognized by a germline-encoded receptor, the activation of which initiates a signaling cascade that leads to the induction of cytokine expression.
  • Innate immune system receptors have broad specificity, recognizing molecular structures that are highly conserved among different pathogens.
  • One family of these receptors is known as Toll-like receptors (TLRs), due to their homology with receptors that were first identified and named in Drosophila , and are present in cells such as macrophages, dendritic cells, and epithelial cells.
  • TLR2 is activated by the lipoprotein of bacteria (e.g., E. coli .)
  • TLR3 is activated by double-stranded RNA
  • TLR4 is activated by lipopolysaccharide (i.e., LPS or endotoxin) of Gram-negative bacteria (e.g., Salmonella and E. coli O157:H7)
  • TLR5 is activated by flagellin of motile bacteria (e.g., Listeria )
  • TLR7 recognizes and responds to imiquimod
  • TLR9 is activated by unmethylated CpG sequences of pathogen DNA.
  • NF- ⁇ B transcription factor- ⁇ B
  • IL-1 interleukin-1
  • the present invention is based, in part, on the discovery by the applicants that a number of small molecules can alter TLR-mediated immunostimulatory signaling. Accordingly, the present application is directed to compounds and pharmaceutical compositions, and methods for use in preventing or treating diseases or conditions characterized by Toll-like receptor 7 (TLR7) activation in patients.
  • TLR7 Toll-like receptor 7
  • the invention features a compound of formula I or II:
  • Formula I can be represented by Formula Ia:
  • Formula II can be represented by Formula IIa:
  • the present application provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof; and a pharmaceutically acceptable carrier or excipient.
  • the present application provides for a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof; at least one additional active agent; and a pharmaceutically acceptable carrier or excipient.
  • the present application provides for a method for treating or preventing a viral infection comprising administering, to a patient in need thereof, a therapeutically effective amount of at least one compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for a combination pharmaceutical agent comprising:
  • a) a first pharmaceutical composition comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof;
  • a second pharmaceutical composition comprising at least one additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HBV/HCV, another drug for treating HBV/HCV, and combinations thereof.
  • additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HBV/HCV, another drug for treating HBV/HCV, and combinations thereof.
  • a compound of the invention or “a compound of formula I or II” means a compound of formula I or II, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
  • a compound of formula (number) means a compound of that formula and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
  • Alkyl is hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms.
  • an alkyl group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 alkyl), 1 to 10 carbon atoms (i.e., C 1 -C 10 alkyl), or 1 to 6 carbon atoms (i.e., C 1 -C 6 alkyl).
  • alkyl groups include, but are not limited to, methyl (Me, —CH 3 ), ethyl (Et, —CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, —CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, —CH(CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, —CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, —CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, —CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, —C(CH 3 ) 3 ), 1-pentyl (n-pentyl, —CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (—CH(CH 3 )
  • Alkoxy means a group having the formula —O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
  • the alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 alkoxy), 1 to 12 carbon atoms (i.e., C 1 -C 12 alkoxy), or 1 to 6 carbon atoms (i.e., C 1 -C 6 alkoxy).
  • alkoxy groups include, but are not limited to, methoxy (—O—CH 3 or —OMe), ethoxy (—OCH 2 CH 3 or —OEt), t-butoxy (—O—C(CH 3 ) 3 or —OtBu) and the like.
  • Haloalkyl is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
  • the alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 haloalkyl), 1 to 12 carbon atoms (i.e., C 1 -C 2 haloalkyl), or 1 to 6 carbon atoms (i.e., C 1 -C 6 alkyl).
  • suitable haloalkyl groups include, but are not limited to, —CF 3 , —CHF 2 , —CFH 2 , —CH 2 CF 3 , and the like.
  • Alkenyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp 2 double bond.
  • an alkenyl group can have 2 to 20 carbon atoms (i.e., C 2 -C 20 alkenyl), 2 to 12 carbon atoms (i.e., C 2 -C 12 alkenyl), or 2 to 6 carbon atoms (i.e., C 2 -C 6 alkenyl).
  • alkenyl groups include, but are not limited to, ethylene, vinyl (—CH ⁇ CH 2 ), allyl (—CH 2 CH ⁇ CH 2 ), cyclopentenyl (—C 5 H 7 ), and 5-hexenyl (—CH 2 CH 2 CH 2 CH 2 CH ⁇ CH 2 ).
  • Alkynyl is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple bond.
  • an alkynyl group can have 2 to 20 carbon atoms (i.e., C 2 -C 20 alkynyl), 2 to 12 carbon atoms (i.e., C 2 -C 12 alkyne,), or 2 to 6 carbon atoms (i.e., C 2 -C 6 alkynyl).
  • suitable alkynyl groups include, but are not limited to, acetylenic (—C ⁇ CH), propargyl (—CH 2 C ⁇ CH), and the like.
  • Alkylene refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • an alkylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkylene radicals include, but are not limited to, methylene (—CH 2 —), 1,1-ethyl (—CH(CH 3 )—), 1,2-ethyl (—CH 2 CH 2 —), 1,1-propyl (—CH(CH 2 CH 3 )—), 1,2-propyl (—CH 2 CH(CH 3 )—), 1,3-propyl (—CH 2 CH 2 CH 2 —), 1,4-butyl (—CH 2 CH 2 CH 2 CH 2 —), and the like.
  • Alkenylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene.
  • alkenylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkenylene radicals include, but are not limited to, 1,2-ethylene (—CH ⁇ CH—).
  • Alkynylene refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
  • an alkynylene group can have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • Typical alkynylene radicals include, but are not limited to, acetylene (—C ⁇ C—), propargyl (—CH 2 C ⁇ C—), and 4-pentynyl (—CH 2 CH 2 CH 2 C ⁇ CH—).
  • Aminoalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an amino radical.
  • “Amidoalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a —NRCOR a group where R is hydrogen or alkyl and R a is alkyl, substituted alkyl, aryl, or substituted aryl as defined herein, e.g., —(CH 2 ) 2 —NHC(O)CH 3 , —(CH 2 ) 3 —NH—C(O)—CH 3 , and the like.
  • Aryl means a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms.
  • Typical aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.
  • “Arylene” refers to an aryl as defined above having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent aryl. Typical arylene radicals include, but are not limited to, phenylene.
  • Arylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp 2 carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkenyl can include, for example, any of the aryl groups disclosed herein, and the alkenyl portion of the arylalkenyl can include, for example, any of the alkenyl groups disclosed herein.
  • the arylalkenyl group can comprise 6 to 20 carbon atoms, e.g., the alkenyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • Arylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also an sp carbon atom, is replaced with an aryl radical.
  • the aryl portion of the arylalkynyl can include, for example, any of the aryl groups disclosed herein, and the alkynyl portion of the arylalkynyl can include, for example, any of the alkynyl groups disclosed herein.
  • the arylalkynyl group can comprise 6 to 20 carbon atoms, e.g., the alkynyl moiety is 1 to 6 carbon atoms and the aryl moiety is 6 to 14 carbon atoms.
  • substituted in reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, etc., for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”, “substituted heterocyclyl”, and “substituted carbocyclyl” means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
  • prodrug refers to any compound that when administered to a biological system generates the drug substance, i.e., active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s).
  • a prodrug is thus a covalently modified analog or latent form of a therapeutically active compound.
  • Heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • a heteroatom e.g., O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g., —OCH 3 , etc.), an amine (e.g., —NHCH 3 , —N(CH 3 ) 2 , etc.), or a thioalkyl group (e.g., —SCH 3 ).
  • heteroalkyl groups are, respectively, an alkyl ether (e.g., —CH 2 CH 2 —O—CH 3 , etc.), an alkyl amine (e.g., —CH 2 NHCH 3 , —CH 2 N(CH 3 ) 2 , etc.), or a thioalkyl ether (e.g., —CH 2 —S—CH 3 ).
  • an alkyl ether e.g., —CH 2 CH 2 —O—CH 3 , etc.
  • alkyl amine e.g., —CH 2 NHCH 3 , —CH 2 N(CH 3 ) 2 , etc.
  • thioalkyl ether e.g., —CH 2 —S—CH 3
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g., —CH 2 CH 2 —OH), an aminoalkyl group (e.g., —CH 2 NH 2 ), or an alkyl thiol group (e.g., —CH 2 CH 2 —SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a C 1 -C 6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • Heterocycle or “heterocyclyl” as used herein includes by way of example and not limitation those heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9 ; The Chemistry of Heterocyclic Compounds, A Series of Monographs ” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566.
  • heterocycle includes a “carbocycle” as defined herein, wherein one or more (e.g.
  • heterocycle or “heterocyclyl” includes saturated rings, partially unsaturated rings, and aromatic rings (i.e., heteroaromatic rings).
  • Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
  • a non-limiting example of a carbonyl substituted heterocyclyl is:
  • heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl(piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • Heterocyclylene refers to a heterocyclyl, as defined herein, derived by replacing a hydrogen atom from a carbon atom or heteroatom of a heterocyclyl, with an open valence.
  • heteroarylene refers to an aromatic heterocyclylene.
  • Heterocyclylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or Sp 3 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkylene-moiety).
  • Typical heterocyclyl alkyl groups include, but are not limited to heterocyclyl-CH 2 —, 2-(heterocyclyl)ethan-1-yl, and the like, wherein the “heterocyclyl” portion includes any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry .
  • heterocyclyl group can be attached to the alkyl portion of the heterocyclyl alkyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkyl group comprises 2 to 20 carbon atoms, e.g., the alkyl portion of the arylalkyl group comprises 1 to 6 carbon atoms and the heterocyclyl moiety comprises 1 to 14 carbon atoms.
  • heterocyclylalkyls include by way of example and not limitation 5-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as thiazolylmethyl, 2-thiazolylethan-1-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.
  • heterocycles such as thiazolylmethyl, 2-thiazolylethan-1-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc.
  • 6-membered sulfur, oxygen, and/or nitrogen containing heterocycles such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl,
  • Heterocyclylalkenyl refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, but also a sp 2 carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclylalkenylene-moiety).
  • the heterocyclyl portion of the heterocyclyl alkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry , and the alkenyl portion of the heterocyclyl alkenyl group includes any of the alkenyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkenyl portion of the heterocyclyl alkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkenyl group comprises 2 to 20 carbon atoms, e.g., the alkenyl portion of the heterocyclyl alkenyl group comprises 1 to 6 carbon atoms and the heterocyclyl moiety comprises 1 to 14 carbon atoms.
  • Heterocyclylalkynyl refers to an acyclic alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or Sp 3 carbon atom, but also an sp carbon atom, is replaced with a heterocyclyl radical (i.e., a heterocyclyl-alkynylene-moiety).
  • the heterocyclyl portion of the heterocyclyl alkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry , and the alkynyl portion of the heterocyclyl alkynyl group includes any of the alkynyl groups disclosed herein.
  • heterocyclyl group can be attached to the alkynyl portion of the heterocyclyl alkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond, with the proviso that the resulting group is chemically stable.
  • the heterocyclyl alkynyl group comprises 2 to 20 carbon atoms, e.g., the alkynyl portion of the heterocyclyl alkynyl group comprises 1 to 6 carbon atoms and the heterocyclyl moiety comprises 1 to 14 carbon atoms.
  • Heteroaryl refers to a monovalent aromatic heterocyclyl having at least one heteroatom in the ring.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen.
  • suitable heteroatoms which can be included in the aromatic ring include oxygen, sulfur, and nitrogen.
  • Non-limiting examples of heteroaryl rings include all of those listed in the definition of “heterocyclyl”, including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl, etc.
  • Carbocycle or “carbocyclyl” refers to a saturated, partially unsaturated or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
  • Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
  • Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo (4,5), (5,5), (5,6) or (6,6) system, or 9 or 10 ring atoms arranged as a bicyclo (5,6) or (6,6) system.
  • Carbocyclylene refers to a carbocyclyl or carbocycle as defined above having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent carbocyclyl.
  • Typical carbocyclylene radicals include, but are not limited to, phenylene.
  • Arylheteroalkyl refers to a heteroalkyl as defined herein, in which a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced with an aryl group as defined herein.
  • the aryl groups may be bonded to a carbon atom of the heteroalkyl group, or to a heteroatom of the heteroalkyl group, provided that the resulting arylheteroalkyl group provides a chemically stable moiety.
  • an arylheteroalkyl group can have the general formulae -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene-S-alkylene-aryl, etc.
  • any of the alkylene moieties in the general formulae above can be further substituted with any of the substituents defined or exemplified herein.
  • Heteroarylalkyl refers to an alkyl group, as defined herein, in which a hydrogen atom has been replaced with a heteroaryl group as defined herein.
  • Non-limiting examples of heteroaryl alkyl include —CH 2 -pyridinyl, —CH 2 -pyrrolyl, —CH 2 -oxazolyl, —CH 2 -indolyl, —CH 2 -isoindolyl, —CH 2 -purinyl, —CH 2 -furanyl, —CH 2 -thienyl, —CH 2 -benzofuranyl, —CH 2 -benzothiophenyl, —CH 2 -carbazolyl, —CH 2 -imidazolyl, —CH 2 -thiazolyl, —CH 2 -isoxazolyl, —CH 2 -pyrazolyl, —CH 2 -isothiazolyl, —CH 2
  • optionally substituted in reference to a particular moiety of the compound of Formula I (e.g., an optionally substituted aryl group) refers to a moiety having 0, 1, 2, or more substituents.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • d and l or (+) and ( ⁇ ) are employed to designate the sign of rotation of plane-polarized light by the compound, with ( ⁇ ) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory.
  • these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • the terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • protecting groups include prodrug moieties and chemical protecting groups.
  • Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group “PG” will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.
  • protecting groups for —OH groups include “ether- or ester-forming groups”.
  • Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein.
  • some hydroxyl and thio protecting groups are neither ether-nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.
  • Ester-forming groups include: (1) phosphonate ester-forming groups, such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates; (2) carboxyl ester-forming groups, and (3) sulphur ester-forming groups, such as sulphonate, sulfate, and sulfinate.
  • phosphonate ester-forming groups such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates
  • carboxyl ester-forming groups such as sulphonate, sulfate, and sulfinate.
  • the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • Such products typically are identified by preparing a radiolabelled (e.g., C 14 or H 3 ) compound of the invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples.
  • a detectable dose e.g., greater than about 0.5 mg/kg
  • an animal such as rat, mouse, guinea pig, monkey, or to man
  • sufficient time for metabolism to occur typically about 30 seconds to 30 hours
  • isolating its conversion products from the urine, blood or other biological samples typically isolating its conversion products from the urine, blood or other biological samples.
  • the metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis.
  • the present application provides compounds according to Formula I or II, as described herein.
  • -L 2 -R 3 is —NH 2 .
  • L 2 is —NR 5 or —O—; and R 3 is heteroalkyl or substituted heteroalkyl.
  • L 2 is —NR 5 or —O—; and R 3 is alkyl or substituted alkyl.
  • L 2 is —NR 5 or —O—; and R 3 is arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl.
  • X 1 is alkylene or substituted alkylene
  • L 1 is arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, carbocyclylene, or substituted carbocyclylene
  • X 2 is alkylene or substituted alkylene.
  • X 1 is alkylene or substituted alkylene
  • L 1 is —S—, —NR 5 —, or —O—
  • X 2 is alkylene or substituted alkylene.
  • X 1 is alkylene or substituted alkylene
  • L 1 is a covalent bond
  • X 2 is a covalent bond, alkylene or substituted alkylene.
  • X 1 is carbocyclylene, substituted carbocyclylene, heterocyclylene, or substituted heterocyclylene; L 1 is a covalent bond; and X 2 is alkylene or substituted alkylene.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 1 and R 2 are each independently H, alkyl, or substituted alkyl.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 1 and R 2 are each independently -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 .
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 2 is carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; R 2 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
  • —Y 1 —R 1 is —O—N ⁇ C(R 6 R 7 ).
  • —Y 1 —R 1 is —O—N ⁇ C(R 6 R 7 ); Y 2 is —O— or —NR 5 —.
  • each R 5 , R 6 , and R 7 are independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl.
  • the present application provides compounds according to Formula Ia, as described herein.
  • —Y 1 —R 1 is —OH.
  • —Y 2 —R 2 is —OH.
  • —Y 1 —R 1 and —Y 2 —R 2 are both —OH.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 1 and R 2 are each independently -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 .
  • L 2 is —O—, —N(R 5 )—, or —S—.
  • L 2 is —O—, —N(R 5 )—, or —S—; and R 3 is alkyl, arylalkyl, or heteroalkyl.
  • L 2 is —O—, —N(R 5 )—, or —S—; and R 3 is —CH 2 CH 2 CH 2 CH 3 .
  • L 2 is —O—, —N(R 5 )—, or —S—; and R 3 is -alkylene-O-alkyl.
  • L 2 is —O—, —N(R 5 )—, or —S—; and R 3 is —CH 2 CH 2 —O—CH 3 .
  • L 2 is —O—, —N(R 5 )—, or —S—; and R 3 is benzyl.
  • L 2 is —O—, —N(R 5 )—, or —S—; and X 1 is alkylene.
  • L 2 is —O—, —N(R 5 )—, or —S—;
  • X 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is —OH.
  • L 1 is arylene or substituted arylene.
  • —X 1 -L 1 - is —CH 2 -phenylene-.
  • X 1 is alkylene; L 1 is —O—.
  • —X 1 -L 1 - is —CH 2 CH 2 —O— or —CH 2 CH(CH 3 )—O—.
  • X 1 is alkylene; L 1 is a covalent bond.
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is alkylene
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • X 1 is alkylene; L 1 is arylene or substituted arylene; X 2 is a covalent bond.
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • X 1 is alkylene; L 1 is —O—; X 2 is alkylene.
  • X 1 is alkylene; L 1 is —O—; X 2 is —CH 2 —.
  • X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • Y 1 and Y 2 are both —O—.
  • Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , -(substituted alkylene)-O—C(O)—O—R 5 , aryl, or substituted aryl.
  • Y 1 and Y 2 are both —O—; R 1 and R 2 are each independently H or alkyl.
  • Y 1 and Y 2 are both —O—; R 1 and R 2 are each H.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —;
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , -(substituted alkylene)-O—C(O)—O—R 5 , aryl, or substituted aryl.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 1 and R 2 are each H.
  • Y 2 is a covalent bond; and R 2 is carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl.
  • Y 2 is a covalent bond; and R 2 is aryl, substituted aryl, substituted or unsubstituted 5- to 7-membered non-aromatic heterocyclyl containing 1 to 4 hetero atoms selected from a group consisting of N, O, S, and a combination thereof.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 2 is carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —; and R 2 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
  • —Y 1 —R 1 is —O—N ⁇ C(R 6 R 7 ).
  • —Y 1 —R 1 is —O—N ⁇ C(CH 3 ) 2 .
  • —Y 1 —R 1 is —O—N ⁇ C(R 6 R 7 ); Y 2 is —O— or —NR 5 —.
  • —Y 1 —R 1 is —O—N ⁇ C(CH 3 ) 2 ; Y 2 is —O— or —NR 5 —.
  • R 4 is —OH, —O—C(O)—O—CH 2 CH 3 , —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 , —NH—CH 2 CH 2 CH 2 CH 3 , —NH 2 —CH 2 CH 2 —N(CH 2 CH 2 ) 2 O, or —SH.
  • X 1 is alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or a covalent bond; L 1 is a covalent bond or arylene; L 2 is —O—; R 1 is H, alkyl, -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is heteroalkyl; and R 4 is —OH.
  • X 1 and X 2 are alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or —NR 5 —; L 1 is arylene; L 2 is —O—; R 1 is H, alkyl, -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is alkyl or heteroalkyl; and R 4 is —NH(R 5 ).
  • X 1 and X 2 are alkylene or substituted alkylene; Y 1 is —O— or —NR 5 —; Y 2 is a covalent bond; and L 1 is arylene or —O—; L 2 is —O—; R 1 is H, alkyl, or substituted alkyl; and R 2 is carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl.
  • X 1 and X 2 are alkylene or substituted alkylene; Y 1 and Y 2 are each independently —O— or —NR 5 —; L 1 is arylene or —O—; L 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 ; and R 2 is carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl.
  • X 1 and X 2 are alkylene or substituted alkylene; Y 1 —R 1 is —O—N ⁇ C(R 6 R 7 ); Y 2 is —O— or —NR 5 —; L 1 is arylene or —O—; L 2 is —O—; and R 2 is -alkylene-C(O)—O—R 5 , -(substituted alkylene)-C(O)—O—R 5 , -alkylene-O—C(O)—R 5 , -(substituted alkylene)-O—C(O)—R 5 , -alkylene-O—C(O)—O—R 5 , or -(substituted alkylene)-O—C(O)—O—R 5 .
  • L 2 is —O—, —N(R 5 )—, or —S—.
  • L 2 is —O—, —N(R 5 )—, or —S—, R 3 is alkyl or heteroalkyl.
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is -alkylene-O-alkyl.
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is —CH 2 CH 2 —O—CH 3 .
  • X 1 is alkylene
  • X 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is —OH.
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene.
  • —X 1 -L 1 - is —CH 2 -phenylene-.
  • X 1 is alkylene, L 1 is —O—.
  • —X 1 -L 1 - is —CH 2 CH 2 —O— or —CH 2 CH(CH 3 )—O—.
  • X 1 is alkylene
  • L 1 is a covalent bond
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is alkylene
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond.
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • X 1 is alkylene
  • L 1 is —O—
  • X 2 is alkylene
  • X 1 is alkylene
  • L 1 is —O—
  • X 2 is —CH 2 —.
  • X 1 is alkylene, L 1 is —O—, X 2 is —CH 2 —, X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • Y 1 and Y 2 are both —O—.
  • Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • Y 1 and Y 2 are both —O—, R 1 and R 2 are each independently H or alkyl.
  • Y 1 and Y 2 are both —O—, R 1 and R 2 are each H.
  • Y 1 and Y 2 are each independently —O— or —NR 5 —, R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • Y 1 is —NR 5 —; Y 2 is —O—; R 1 is alkyl or -alkylene-C(O)—O—R 5 ; and R 2 is aryl or substituted aryl.
  • Y 1 is —NR 5 —; Y 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is aryl.
  • X 1 is alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or a covalent bond; L 1 is a covalent bond or arylene; L 2 is —O—; R 1 is H, alkyl, or -alkylene-C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is heteroalkyl; and R 4 is —OH.
  • X 1 is alkylene; Y 1 and Y 1 are both —O—; R 1 and R 2 are both H; and L 1 is phenylene.
  • X 1 is alkylene; Y 1 and Y 1 are both —O—; R 1 and R 2 are both H; and L 1 and X 2 are both a covalent bond.
  • X 1 is alkylene; Y 1 and Y 1 are both —O—; L 1 is —O—; R 1 is H or alkyl; R 2 is H; and X 2 is alkylene.
  • X 1 is alkylene; Y 1 is —O—; Y 2 is a covalent bond; L 1 is phenylene; R 1 is H; R 2 is aryl; and X 2 is alkylene.
  • X 1 is alkylene; Y 1 is —NH—;
  • X 1 and X 2 are alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or —NR 5 —; L 1 is arylene; L 2 is —O—; R 1 is H, alkyl, or -alkylene-C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is alkyl or heteroalkyl; and R 4 is —NH(R 5 ).
  • R 4 is OH
  • L 2 is —O—, —N(R 5 )—, or —S—.
  • R 4 is OH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is alkyl or heteroalkyl, wherein the alkyl and heteroalkyl are any alkyl and heteroalkyl defined and exemplified herein.
  • Non-limiting examples of alkyl or substituted alkyl include —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH(alkyl), —CH(substituted alkyl), —CH(heteroalkyl), —C(alkyl) 2 , —C(substituted alkyl) 2 , —C(heteroalkyl) 2 , —C(alkyl) (substituted alkyl), —C(heteroalkyl) (substituted alkyl), and —C(alkyl)(heteroalkyl), wherein alkyl, substituted alkyl, and heteroalkyl are as defined and exemplified herein.
  • Non-limiting examples of alkyl or substituted alkyl include —OCH 3 , —NHCH 3 , —N(CH 3 ) 2 , —SCH 3 , —CH 2 CH 2 —O—CH 3 , —CH 2 NHCH 3 , —CH 2 N(CH 3 ) 2 , —CH 2 —S—CH 3 , —CH 2 CH 2 —OH, —CH 2 NH 2 , and —CH 2 CH 2 —SH.
  • R 4 is OH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is -alkylene-O-alkyl.
  • R 4 is OH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is —CH 2 CH 2 —O—CH 3 .
  • R 4 is OH
  • X 1 is alkylene
  • R 4 is OH
  • X 1 is —CH 2 —, —CH 2 Cl 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is OH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene.
  • R 4 is OH, —X 1 -L 1 - is —CH 2 -phenylene-.
  • R 4 is OH, X 1 is alkylene, L 1 is —O—.
  • R 4 is OH, —X 1 -L 1 - is —CH 2 CH 2 —O— or —CH 2 CH(CH 3 )—O—.
  • R 4 is OH
  • X 1 is alkylene
  • L 1 is a covalent bond.
  • R 4 is OH, X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is alkylene.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • R 4 is OH, X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond.
  • R 4 is OH, X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • R 4 is OH, X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • R 4 is OH, X 1 is alkylene, L 1 is —O—, X 2 is alkylene.
  • R 4 is OH, X 1 is alkylene, L 1 is —O—, X 2 is —CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH 2 — or —CH(CH 3 )—O—CH 2 CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 CH(aryl)-O—CH 2 — or —CH 2 CH(substituted-aryl)-O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH(aryl)CH 2 —O—CH 2 — or —CH(substituted-aryl)CH 2 —O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH(aryl)CH 2 — or —CH 2 —O—CH(substituted-aryl)CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(aryl)- or —CH 2 —O—CH 2 CH(substituted-aryl)-.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 CH(arylalkyl)-O—CH 2 — or —CH 2 CH(substituted-arylalkyl)-O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH(arylalkyl)CH 2 —O—CH 2 — or —CH(substituted-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH(arylalkyl)CH 2 — or —CH 2 —O—CH(substituted arylalkyl)CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(arylalkyl)- or —CH 2 —O—CH 2 CH(substituted-arylalkyl)-.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 CH(—O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted —O-arylalkyl)-O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH(—O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted —O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH(—O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted-O-arylalkyl)CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(—O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted —O-arylalkyl)-.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 CH(-alkylene-O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted -alkylene-O-arylalkyl)-O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH(-alkylene-O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted -alkylene-O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH(-alkylene-O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted alkylene-O-arylalkyl)CH 2 —.
  • R 4 is OH, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(-alkylene-O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted alkylene-O-arylalkyl)-.
  • R 4 is OH, Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • R 4 is OH, Y 1 and Y 2 are both —O—.
  • R 4 is OH, Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 4 is OH
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is OH, Y 1 and Y 2 are both —O—, R 1 and R 2 are each independently H or alkyl.
  • R 4 is OH, Y 1 and Y 2 are both —O—, R 1 and R 2 are each H.
  • R 4 is OH, Y 1 and Y 2 are each independently —O— or —NR 5 —, R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is OH, Y 1 is —NR 5 —; Y 2 is —O—; R 1 is alkyl or -alkylene-C(O)—O—R 5 ; and R 2 is aryl or substituted aryl.
  • R 4 is OH, Y 1 is —NR 5 —; Y 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is aryl.
  • R 4 is OH, Y 1 is —O—; Y 2 is a covalent bond; R 1 is H; and R 2 is alkyl, aryl, or substituted aryl.
  • R 4 is OH, X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 is phenylene.
  • R 4 is OH, X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 and X 2 are both a covalent bond.
  • R 4 is OH, X 1 is alkylene; Y 1 and Y 2 are both —O—; L 1 is —O—; R 1 is H or alkyl; R 2 is H; and X 2 is alkylene.
  • R 4 is OH, X 1 is alkylene; Y 1 is —O—; Y 2 is a covalent bond; L 1 is phenylene; R 1 is H; R 2 is aryl; and X 2 is alkylene.
  • R 4 is OH, X 1 is alkylene; Y 1 is —NH—; Y 2 is —O—; L 1 is phenylene; X 2 is alkylene; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is phenyl.
  • X 1 and X 2 are alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or —NR 5 —; L 1 is arylene; L 2 is —O—; R 1 is H, alkyl, or -alkylene-C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is alkyl or heteroalkyl; and R 4 is —NH(R 5 ).
  • R 4 is —NH(R 5 ), L 2 is —O—, —N(R 5 )—, or —S—.
  • R 4 is —NH(R 5 ), L 2 is —O—, —N(R 5 )—, or —S—, R 3 is alkyl or heteroalkyl, wherein the alkyl and heteroalkyl are any alkyl and heteroalkyl defined and exemplified herein.
  • R 4 is —NH(R 5 ), L 2 is —O—, —N(R 5 )—, or —S—, R 3 is -alkylene-O-alkyl.
  • R 4 is —NH(R 5 ), L 2 is —O—, —N(R 5 )—, or —S—, R 3 is —CH 2 CH 2 —O—CH 3 .
  • R 4 is —NH(R 5 ), X 1 is alkylene.
  • R 4 is —NH(R 5 ), X 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is arylene or substituted arylene.
  • R 4 is —NH(R 5 ), —X 1 -L 1 - is —CH 2 -phenylene-.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is —O—.
  • R 4 is —NH(R 5 ), —X 1 -L 1 - is —CH 2 CH 2 O— or —CH 2 CH(CH 3 )—.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is a covalent bond.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is alkylene.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is —, X 2 is alkylene.
  • R 4 is —NH(R 5 ), X 1 is alkylene, L 1 is —, X 2 is —CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH 2 — or —CH(CH 3 )—O—CH 2 CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 CH(aryl)-O—CH 2 — or —CH 2 CH(substituted-aryl)-O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH(aryl)CH 2 —O—CH 2 — or —CH(substituted-aryl)CH 2 —O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH(aryl)CH 2 — or —CH 2 —O—CH(substituted-aryl)CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(aryl)- or —CH 2 —O—CH 2 CH(substituted-aryl)-.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 CH(arylalkyl)-O—CH 2 — or —CH 2 CH(substituted-arylalkyl)-O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH(arylalkyl)CH 2 —O—CH 2 — or —CH(substituted-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH(arylalkyl)CH 2 — or —CH 2 —O—CH(substituted arylalkyl)CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(arylalkyl)- or —CH 2 —O—CH 2 CH(substituted-arylalkyl)-.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 CH(—O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted —O-arylalkyl)-O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH(—O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted —O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH(—O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted-O-arylalkyl)CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(—O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted —O-arylalkyl)-.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 CH(-alkylene-O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted -alkylene-O-arylalkyl)-O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH(-alkylene-O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted -alkylene-O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH(-alkylene-O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted alkylene-O-arylalkyl)CH 2 —.
  • R 4 is —NH(R 5 ), X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(-alkylene-O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted alkylene-O-arylalkyl)-.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are both —O—.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 4 is —NH(R 5 ), R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are both —O—, R 1 and R 2 are each independently H or alkyl.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are both —O—, R 1 and R 2 are each H.
  • R 4 is —NH(R 5 ), Y 1 and Y 2 are each independently —O— or —NR 5 —, R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is —NH(R 5 ), Y 1 is —NR 5 —; Y 2 is —O—; R 1 is alkyl or -alkylene-C(O)—O—R 5 ; and R 2 is aryl or substituted aryl.
  • R 4 is —NH(R 5 ), Y 1 is —NR 5 —; Y 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is aryl.
  • R 4 is —NH(R 5 ), Y 1 is —O—; Y 2 is a covalent bond; R 1 is H; and R 2 is alkyl, aryl, or substituted aryl.
  • R 4 is —NH(R 5 ), X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 is phenylene.
  • R 4 is —NH(R 5 ), X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 and X 2 are both a covalent bond.
  • R 4 is —NH(R 5 ), X 1 is alkylene; Y 1 and Y 2 are both —O—; L 1 is —; R 1 is H or alkyl; R 2 is H; and X 2 is alkylene.
  • R 4 is —NH(R 5 ), X 1 is alkylene; Y 1 is —O—; Y 2 is a covalent bond; L 1 is phenylene; R 1 is H; R 2 is aryl; and X 2 is alkylene.
  • R 4 is —NH(R 5 ), X 1 is alkylene; Y 1 is —NH—; Y 2 is —O—; L 1 is phenylene; X 2 is alkylene; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is phenyl.
  • X 1 and X 2 are alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or —NR 5 —; L 1 is arylene; L 2 is —O—; R 1 is H, alkyl, or -alkylene-C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is alkyl or heteroalkyl; and R 4 is —SH.
  • R 4 is —SH
  • L 2 is —O—, —N(R 5 )—, or —S—.
  • R 4 is —SH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is alkyl or heteroalkyl, wherein the alkyl and heteroalkyl are any alkyl and heteroalkyl defined and exemplified herein.
  • R 4 is —SH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is -alkylene-O-alkyl.
  • R 4 is —SH
  • L 2 is —O—, —N(R 5 )—, or —S—
  • R 3 is —CH 2 CH 2 —O—CH 3 .
  • R 4 is —SH
  • X 1 is alkylene
  • R 4 is —SH
  • X 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene.
  • R 4 is —SH, —X 1 -L 1 - is —CH 2 -phenylene-.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is —O—.
  • R 4 is —SH
  • —X 1 -L 1 - is —CH 2 CH 2 —O— or —CH 2 CH(CH 3 )—O—.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is a covalent bond.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is alkylene
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond
  • X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is arylene or substituted arylene
  • X 2 is a covalent bond
  • X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is —O—
  • X 2 is alkylene
  • R 4 is —SH
  • X 1 is alkylene
  • L 1 is —O—
  • X 2 is —CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH 2 — or —CH(CH 3 )—O—CH 2 CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 CH(aryl)-O—CH 2 — or —CH 2 CH(substituted-aryl)-O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH(aryl)CH 2 —O—CH 2 — or —CH(substituted-aryl)CH 2 —O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH(aryl)CH 2 — or —CH 2 —O—CH(substituted-aryl)CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(aryl)- or —CH 2 —O—CH 2 CH(substituted-aryl)-.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 CH(arylalkyl)-O—CH 2 — or —CH 2 CH(substituted-arylalkyl)-O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH(arylalkyl)CH 2 —O—CH 2 — or —CH(substituted-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH(arylalkyl)CH 2 — or —CH 2 —O—CH(substituted arylalkyl)CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(arylalkyl)- or —CH 2 —O—CH 2 CH(substituted-arylalkyl)-.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 CH(—O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted —O-arylalkyl)-O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH(—O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted —O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH(—O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted-O-arylalkyl)CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(—O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted —O-arylalkyl)-.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 CH(-alkylene-O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted -alkylene-O-arylalkyl)-O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH(-alkylene-O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted -alkylene-O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH(-alkylene-O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted alkylene-O-arylalkyl)CH 2 —.
  • R 4 is —SH
  • X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(-alkylene-O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted alkylene-O-arylalkyl)-.
  • R 4 is —SH, Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • R 4 is —SH, Y 1 and Y 2 are both —O—.
  • R 4 is —SH, Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 4 is —SH
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is —SH, Y 1 and Y 2 are both —O—, R 1 and R 2 are each independently H or alkyl.
  • R 4 is —SH, Y 1 and Y 2 are both —O—, R 1 and R 2 are each H.
  • R 4 is —SH
  • Y 1 and Y 2 are each independently —O— or —NR 5 —
  • R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is —SH, Y 1 is —NR 5 —; Y 2 is —O—; R 1 is alkyl or -alkylene-C(O)—O—R 5 ; and R 2 is aryl or substituted aryl.
  • R 4 is —SH, Y 1 is —NR 5 —; Y 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is aryl.
  • R 4 is —SH, Y 1 is —O—; Y 2 is a covalent bond; R 1 is H; and R 2 is alkyl, aryl, or substituted aryl.
  • R 4 is —SH
  • X 1 is alkylene
  • Y 1 and Y 2 are both —O—
  • R 1 and R 2 are both H
  • L 1 is phenylene
  • R 4 is —SH
  • X 1 is alkylene
  • Y 1 and Y 2 are both —O—
  • R 1 and R 2 are both H
  • L 1 and X 2 are both a covalent bond.
  • R 4 is —SH, X 1 is alkylene; Y 1 and Y 2 are both —O—; L 1 is —O—; R 1 is H or alkyl; R 2 is H; and X 2 is alkylene.
  • R 4 is —SH, X 1 is alkylene; Y 1 is —O—; Y 2 is a covalent bond; L 1 is phenylene; R 1 is H; R 2 is aryl; and X 2 is alkylene.
  • R 4 is —SH
  • X 1 is alkylene
  • Y 1 is —NH—
  • Y 2 is —O—
  • L 1 is phenylene
  • X 2 is alkylene
  • R 1 is -alkylene-C(O)—O—R 5
  • R 2 is phenyl
  • R 4 is OH, and X 1 -L 1 -X 2 —P(O)(Y 1 R 1 )(Y 2 R 2 ) is:
  • Z 2 is selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy.
  • R 4 is OH, —SH, —NH(R 5 ), X 1 and X 2 are alkylene; Y 1 is —O— or —NR 5 —; Y 2 is —O— or —NR 5 —; L 1 is arylene; R 1 is H, alkyl, or -alkylene-C(O)—O—R 5 ; R 2 is H, alkyl, or aryl; R 3 is alkyl or heteroalkyl; L 2 is a bond, R 3 is a substituted alkyl, wherein the substituted alkyl is alkyl defined or exemplified herein.
  • the substituents may include amino, amido, heteroalkyl, etc.
  • Non-limiting examples of substituted alkyl include —CH 2 —NH 2 , —CH 2 —NH—C(O)—CH 3 , —CH 2 —C(O)—NH—CH 3 , —CH 2 —CH 2 —NH—C(O)—CH 3 , —CH 2 —CH 2 —C(O)—NH—CH 3 , —CH 2 —NH—C(O)—CH 2 —CH 3 , —CH 2 —C(O)—NH—CH 2 —CH 3 , —CH 2 CH 2 —O—CH 3 , —CH 2 CH(CH 3 )—O—CH 3 , —CH 2 —O—CH 2 —CH 3 , —CH 2 —O—CH(CH 3 )CH 3 , —CH 2 CH 2 —S—CH 3 or —CH 2 —S—CH(CH 3 )CH 3 , —CH 2 —S—CH 2 CH 3 or —CH 2 CH 2
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent, R 3 is —CH 2 —NH 2 , —CH 2 —NH—C(O)—CH 3 , X 1 is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 2 )—.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , —X 1 -L 1 - is —CH 2 -phenylene-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , —X 1 -L 1 - is —CH 2 CH 2 —O— or —CH 2 CH(CH 3 )—O—.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is a covalent bond.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is alkylene.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 -L 1 -X 2 — is —CH 2 -phenylene-CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)-CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 , or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -phenylene-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is arylene or substituted arylene, X 2 is a covalent bond, X 1 -L 1 -X 2 — is —CH 2 -(1,3-phenylene)- or —CH 2 -(1,4-phenylene)-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is —O—, X 2 is alkylene.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, L 1 is —O—, X 2 is —CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 — or —CH 2 CH(CH 3 )—O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH 2 — or —CH(CH 3 )—O—CH 2 CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 CH(aryl)-O—CH 2 — or —CH 2 CH(substituted-aryl)-O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH(aryl)CH 2 —O—CH 2 — or —CH(substituted-aryl)CH 2 —O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH(aryl)CH 2 — or —CH 2 —O—CH(substituted-aryl)CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(aryl)- or —CH 2 —O—CH 2 CH(substituted-aryl)-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 CH(arylalkyl)-O—CH 2 — or —CH 2 CH(substituted-arylalkyl)-O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH(arylalkyl)CH 2 —O—CH 2 — or —CH(substituted-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH(arylalkyl)CH 2 — or —CH 2 —O—CH(substituted arylalkyl)CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(arylalkyl)- or —CH 2 —O—CH 2 CH(substituted-arylalkyl)-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 CH(—O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted —O-arylalkyl)-O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH(—O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted —O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH(—O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted-O-arylalkyl)CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(—O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted —O-arylalkyl)-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 CH(-alkylene-O-arylalkyl)-O—CH 2 — or —CH 2 CH(substituted -alkylene-O-arylalkyl)-O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH(-alkylene-O-arylalkyl)CH 2 —O—CH 2 — or —CH(substituted -alkylene-O-arylalkyl)CH 2 —O—CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH(-alkylene-O-arylalkyl)CH 2 — or —CH 2 —O—CH(substituted alkylene-O-arylalkyl)CH 2 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene, X 1 -L 1 -X 2 — is —CH 2 —O—CH 2 CH(-alkylene-O-arylalkyl)- or —CH 2 —O—CH 2 CH(substituted alkylene-O-arylalkyl)-.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are each independently —O— or —NR 5 —.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are both —O—.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are each independently —O— or a covalent bond.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are both —O—, R 1 and R 2 are each independently H or alkyl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are both —O—, R 1 and R 2 are each H.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 and Y 2 are each independently —O— or —NR 5 —, R 1 and R 2 are each independently H, alkyl, -alkylene-C(O)—O—R 5 , aryl, or substituted aryl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 is —NR 5 —; Y 2 is —O—; R 1 is alkyl or -alkylene-C(O)—O—R 5 ; and R 2 is aryl or substituted aryl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 is —NR 5 —; Y 2 is —O—; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is aryl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , Y 1 is —O—; Y 2 is a covalent bond; R 1 is H; and R 2 is alkyl, aryl, or substituted aryl.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 is phenylene.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene; Y 1 and Y 2 are both —O—; R 1 and R 2 are both H; and L 1 and X 2 are both a covalent bond.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene; Y 1 and Y 2 are both —O—; L 1 is —O—; R 1 is H or alkyl; R 2 is H; and X 2 is alkylene.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene; Y 1 is —O—; Y 2 is a covalent bond; L 1 is phenylene; R 1 is H; R 2 is aryl; and X 2 is alkylene.
  • R 4 is OH, —SH, or —NH(R 5 ), L 2 is a covalent bond, R 3 is —CH 2 —NH 2 or —CH 2 —NH—C(O)—CH 3 , X 1 is alkylene; Y 1 is —NH—; Y 2 is —O—; L 1 is phenylene; X 2 is alkylene; R 1 is -alkylene-C(O)—O—R 5 ; and R 2 is phenyl.
  • each R 5 , R 6 , and R 7 are independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl.
  • the compound is selected from the group consisting of:
  • the present application provides compounds according to Formula IIa, as described herein.
  • X 1 is alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, or substituted alkynylene.
  • X 1 is —CH 2 — or —CH 2 CH 2 —.
  • X 1 is carbocyclylene, substituted carbocyclylene, heterocyclylene, or substituted heterocyclylene.
  • X 1 is wherein Z is O, NR 7 , or S; each R 6 is independently halo, hydroxyl, amino, cyano, alkyl, substituted alkyl, alkoxy, N-alkyl amino, N,N-dialkyl amino, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl; R 7 is H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalky
  • L 1 is a covalent bond.
  • L 1 is —NR 3 — or —O—.
  • L 1 is arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, carbocyclylene, or substituted carbocyclylene.
  • L 1 is wherein m is 0, 1, 2, 3, or 4; and each R 6 is independently H, halo, hydroxyl, amino, cyano, alkyl substituted alkyl, alkoxy, N-alkyl amino, N,N-dialkyl amino, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl.
  • Y 1 is a covalent bond; and Y 2 is —O— or —NR 4 —.
  • Y 1 is —O—; and Y 2 NR 4 —.
  • Y 1 and Y 2 are both —O—.
  • Y 1 and Y 2 are both —NR 4 —.
  • R 1 and R 2 are each independently H, alkyl, or substituted alkyl.
  • X 1 is alkylene or substituted alkylene
  • L 1 is a covalent bond
  • X 2 is a covalent bond, alkylene, or substituted alkylene.
  • —X 1 -L 1 -X 2 — is —CH 2 CH 2 —.
  • X 1 is alkylene or substituted alkylene; L 1 is a covalent bond; and X 2 is a covalent bond, alkylene, or substituted alkylene; Y 1 and Y 2 are both —O—; and R 1 and R 2 are each independently H, alkyl, or substituted alkyl.
  • X 1 is alkylene or substituted alkylene
  • L 1 is —NR 3 — or —O—
  • X 2 is a covalent bond, alkylene, or substituted alkylene.
  • —X 1 -L 1 -X 2 — is —CH 2 CH 2 —O—CH 2 —.
  • X 1 is alkylene or substituted alkylene
  • L 1 is —NR 3 — or —O—
  • X 2 is a covalent bond, alkylene, or substituted alkylene
  • Y 1 and Y 2 are both —O—
  • R 1 and R 2 are each independently H, alkyl, or substituted alkyl.
  • X 1 is alkylene or substituted alkylene
  • L 1 is arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, carbocyclylene, or substituted carbocyclylene
  • X 2 is a covalent bond, alkylene, or substituted alkylene.
  • X 1 is carbocyclylene, substituted carbocyclylene, heterocyclylene, or substituted heterocyclylene; L 1 is a covalent bond; and X 2 is a covalent bond, alkylene, or substituted alkylene.
  • X 1 is carbocyclylene, substituted carbocyclylene, heterocyclylene, or substituted heterocyclylene;
  • L 1 is a covalent bond;
  • X 2 is a covalent bond, alkylene, or substituted alkylene;
  • Y 1 and Y 2 are both —O—; and
  • R 1 and R 2 are each independently H, alkyl, or substituted alkyl.
  • each R 3 , R 4 , and R 1 are independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, or substituted heterocyclylalkyl.
  • the compound is selected from the group consisting of:
  • Compounds of general Formula I or II are depicted as a “core” structure (C) substituted with four moieties T1, T2, T3 and T4.
  • the core structures C are depicted in Table 1.
  • the points of attachment of T1, T2, T3 and T4 are indicated on each of the core structures depicted in Table 1.
  • Tables 2-5 respectively, show the structures of the T1, T2, T3 and T4 moieties.
  • the point of attachment of the core structure C is indicated in each of the structures of T1, T2, T3 and T4.
  • the core structure C in Table 1, and each substituent T1, T2, T3 and T4 in Tables 2-5 are represented by a “code” comprising a letter and a number.
  • T1A, T2A, T3A and T4A represents the following structure:
  • Alk means a substituted or unsubstituted alkyl or alkylene group, wherein the terms “alkyl” and “alkylene” are as defined herein. “Alk” means an alkyl group when depicted as monovalent, and an alkylene group when depicted as divalent.
  • Het is a substituted or unsubstituted heterocyclyl or heterocyclylene group, wherein the term “heterocyclyl” is as defined herein, and the term “heterocyclylene” means a heterocyclyl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent heterocyclyl.
  • Het is a heterocyclyl when depicted as monovalent, and heterocyclylene when depicted as divalent.
  • “Ar” is a substitute or unsubstituted aryl or arylene group, wherein the term “aryl” is as defined herein, and the term “arylene” means an aryl group as defined herein, in which a hydrogen atom has been replaced by an open valence (in analogy to alkylene), thereby defining a divalent aryl.
  • “Ar” is aryl when depicted as monovalent, and arylene when depicted as divalent. When substituted, “Alk”, “Het”, and “Ar” can be substituted with any of the substituents defined or exemplified herein.
  • substituents of “Alk” can include ether, halogen, —OH, amide, amine, etc.
  • substituents of “Het” can include alkyl, aryl, carbonyl, —OH, halogen
  • substituents of “Ar” can include alkyl, aryl, —OH, halogen, etc., with the proviso that the resulting structure is chemically reasonable, and would provide compounds which are sufficiently stable for formulation in a pharmaceutically acceptable composition.
  • T1A O-alkyl
  • T1B O-alkylene-O-alkyl
  • T1C S-alkyl
  • T1D NH-substituted or unsubstituted alkyl
  • T3B -alkylene-O-alkylene-T4 substituted or unsubstituted
  • T3C substituted or unsubstituted
  • T3D -alkylene-arylene-T4
  • T3E -alkylene-carbocyclylene-alkylene-T4 (substituted or unsubstituted)
  • T3F alkylene-heteroarylene-alkylene-T4 (substituted or unsubstituted)
  • T3G alkylene-heteroarylene-T4 (substituted or unsubstituted)
  • T4A P(O)(OH) 2
  • T4B P(O)(O-aryl)(NH-substituted or unsubstituted alkylene-C(O)—O-alkyl)
  • T4C P(O)(substituted or unsubstituted alkyl)(OH)
  • T4D P(O)(aryl)(O-substituted or unsubstituted alkyl)
  • T4E P(O)(NH-substituted or unsubstituted alkylene-C(O)—O-alkyl) 2
  • T4F P(O)(arylalkyl)(OH)
  • the compounds of the present invention can have one of the structures shown in Table 1.1, wherein M represents alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl; and Z represents halo, alkyl, haloalkyl, or alkoxy.
  • Pd 1 and Pd 2 are each independently selected from species in Tables 20.1 to 20.37.
  • the variables used in Tables 20.1 to 20.37 e.g., W 3 , R 1 , etc.
  • Tables 20.1-20.37 unless otherwise indicated.
  • Additional phosphonate groups are disclosed in U.S. patent publication No. 2004/100960, the entirety of which is incorporated herein by reference.
  • R 1 is independently H or alkyl of 1 to 18 carbon atoms
  • R 2 is independently H, R 1 , R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups;
  • R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ;
  • R 3a is F, Cl, Br, I, —CN, N3 or —NO 2 ;
  • R 3b is Y 1 ;
  • R 3c is —R x , —N(R x )(R x ), —SR x , —S(O)R x , —S(O) 2 R x , —S(O)(OR x ), —S(O) 2 (OR x ), —OC(Y 1 )R x , —OC(Y 1 )OR x , —OC(Y 1 )(N(R x )(R x )), —SC(Y 1 )R x , —SC(Y 1 )OR x , —SC(Y 1 )(N(R x )(R x )), N(R x )C(Y 1 )R x , —N(R x )C(Y 1 )OR x , or —N(R x )C(Y 1 )(N(R x )(R x ));
  • R 3d is —C(Y 1 )R x , —C(Y 1 )OR x or —C(Y 1 )(N(R x )(R x ));
  • R 4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;
  • R 5 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups;
  • R 5a is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R 3 groups;
  • W 3 is W 4 or W 5 ;
  • W 4 is R 5 , —C(Y 1 )R 5 , —C(Y 1 )W 5 , —SO 2 R 5 , or —SO 2 W 5 ;
  • W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups;
  • W 6 is W 3 independently substituted with 1, 2, or 3 A 3 groups
  • M2 is 0, 1 or 2;
  • M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • M1a, M1c, and M1d are independently 0 or 1;
  • M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
  • Sc is Formula A; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 , Pd 2 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 .
  • Sc is Formula A; Pd 1 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 , Pd 2 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 .
  • Sc is Formula A; Pd 1 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 , Pd 2 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 .
  • Sc is Formula B; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 12 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 , Pd 2 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 .
  • Sc is Formula B; Pd 1 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 , Pd 2 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 .
  • Sc is Formula B; Pd 1 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 , Pd 2 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 .
  • Sc is Formula C; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 , Pd 2 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 .
  • Sc is Formula C; Pd 1 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 , Pd 2 is —CH 2 —O—C(O)—O—CH 2 CH 3 .
  • Sc is Formula C; Pd 1 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 , Pd 2 is —CH 2 —O—C(O)—C(CH 3 ) 3 .
  • Sc is Formula D; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —O-Ph; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —O-Ph; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(CH 3 )—C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 3 ; Pd 2 is —NH—CH(benzyl)-C(O)—O—CH 2 CH 2 CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 , Pd 2 is —O—CH 2 —O—C(O)—O—CH(CH 3 ) 2 .
  • Sc is Formula D; Pd 1 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 , Pd 2 is —O—CH 2 —O—C(O)—O—CH 2 CH 3 .
  • Sc is Formula D; Pd 1 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 , Pd 2 is —O—CH 2 —O—C(O)—C(CH 3 ) 3 .
  • A, X, Y and Z are defined in Tables 7-10, below.
  • Each compound is designated in tabular form by combining the “code” representing each structural moiety using the following syntax: A.X.Y.Z
  • A1.X1.Y1.Z1. represents the following structure: TABLE 7 “A” Structures Code “A” Structure A1 A2 A3 A4 A5
  • the compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice.
  • Tablets will contain excipients, glidants, fillers, binders and the like.
  • Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986), herein incorporated by reference in its entirety.
  • Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • the pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.
  • the formulations of the invention both for veterinary and for human use, comprise at least one active ingredient, together with one or more acceptable carriers and optionally other therapeutic ingredients.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
  • the formulations include those suitable for the foregoing administration routes.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.), herein incorporated by reference in its entirety. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be administered as a bolus, electuary or paste.
  • a tablet is made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.
  • compositions according to the present invention comprise one or more compounds of the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration.
  • tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate
  • granulating and disintegrating agents such as maize starch, or alginic acid
  • binding agents such as cellulose, microcrystalline cellulose, starch,
  • Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
  • a suspending agent
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth herein, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent e.g., sodium tartrate
  • suspending agent e.g., sodium EDTA
  • preservatives e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • a non-toxic parenterally acceptable diluent or solvent such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid may likewise be used in the preparation of injectables.
  • a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 Mm (including particle sizes in a range between 0.1 and 500 ⁇ m in increments such as 0.5 Mm, 1 Mm, 30 Mm, 35 Mm, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of infections as described herein.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provided compositions comprising one or more compounds of the invention formulated for sustained or controlled release.
  • the effective dose of an active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.
  • the effective dose can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg/kg body weight per day.
  • the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, or between 5 mg and 500 mg, and may take the form of single or multiple doses.
  • compositions comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or excipient.
  • compositions comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional active agent, and a pharmaceutically acceptable carrier or excipient.
  • the present application discloses pharmaceutical compositions comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional active agent, and a pharmaceutically acceptable carrier or excipient, wherein the additional active agent is selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • additional active agent is selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • interferons examples include, but are not limited to pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN-beta;
  • ribavirin analogs examples include, but are not limited to rebetol, copegus, and viramidine (taribavirin);
  • NS5b polymerase inhibitors examples include, but are not limited to NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, and GSK625433;
  • HCV NS3 protease inhibitors include, but are not limited to SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, and ITMN-191;
  • alpha-glucosidase 1 inhibitors examples include, but are not limited to MX-3253 (celgosivir) and UT-231B;
  • hepatoprotectants include, but are not limited to IDN-6556, ME 3738, LB-84451, and MitoQ;
  • non-nucleoside inhibitors of HCV include, but are not limited to benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, GS-9190, A-831, and A-689; and
  • Examples of the other drugs for treating HCV include, but are not limited to zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
  • the present application provides a combination pharmaceutical agent comprising:
  • a) a first pharmaceutical composition comprising a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, or ester thereof;
  • a second pharmaceutical composition comprising at least one additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • One or more compounds of the invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient.
  • An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.
  • the compounds of the present invention are used in combination with other active therapeutic ingredients or agents.
  • Combinations of the compounds of Formula I or II and additional active agents may be selected to treat patients with a viral infection, e.g., HBV, HCV, or HIV infection.
  • the other active therapeutic ingredients or agents are interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • Combinations of the compounds of Formula I or II are typically selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination. For example, when treating an infection (e.g., HCV), the compositions of the invention are combined with other active agents (such as those described herein).
  • an infection e.g., HCV
  • other active agents such as those described herein.
  • Suitable active agents or ingredients which can be combined with the compounds of Formula I or II can include interferons, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN-beta; ribavirin analogs, e.g., rebetol, copegus, and viramidine (taribavirin); NS5b polymerase inhibitors, e.g., NM-283, val
  • compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional active agent, and a pharmaceutically acceptable carrier or excipient.
  • the active agent used in combination with the compound of the present invention can be any agent having a therapeutic effect when used in combination with the compound of the present invention.
  • the active agent used in combination with the compound of the present invention can be interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • the present application provides pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, in combination with at least one additional active agent selected from the group consisting of interferons, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN-beta; ribavirin analogs, e.g., rebetol, copegus,
  • the present application provides a combination pharmaceutical agent comprising:
  • a) a first pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, or ester thereof;
  • a second pharmaceutical composition comprising at least one additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • one or more compounds of the present invention may be combined with one or more compounds selected from the group consisting of interferons, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN-beta; ribavirin analogs, e.g., rebetol, copegus, and viramidine (taribavirin); NS5b polymerase inhibitors, e.g., NM
  • any compound of the invention with one or more other active agents in a unitary dosage form for simultaneous or sequential administration to a patient.
  • the combination therapy may be administered as a simultaneous or sequential regimen.
  • the combination When administered sequentially, the combination may be administered in two or more administrations.
  • Co-administration of a compound of the invention with one or more other active agents generally refers to simultaneous or sequential administration of a compound of the invention and one or more other active agents, such that therapeutically effective amounts of the compound of the invention and one or more other active agents are both present in the body of the patient.
  • Co-administration includes administration of unit dosages of the compounds of the invention before or after administration of unit dosages of one or more other active agents, for example, administration of the compounds of the invention within seconds, minutes, or hours of the administration of one or more other active agents.
  • a unit dose of a compound of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active agents.
  • a unit dose of one or more other active agents can be administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes.
  • a unit dose of a compound of the invention may be desirable to administer a unit dose of a compound of the invention first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more other active agents. In other cases, it may be desirable to administer a unit dose of one or more other active agents first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention.
  • the combination therapy may provide “synergy” and “synergistic effect”, i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
  • a synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
  • a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g., in separate tablets, pills or capsules, or by different injections in separate syringes.
  • an effective dosage of each active ingredient is administered sequentially, i.e. serially
  • effective dosages of two or more active ingredients are administered together.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with HCV with an effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, whereby HCV polymerase is inhibited.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with HCV with an effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active agent, whereby HCV polymerase is inhibited.
  • the present application provides for methods of inhibiting HCV polymerase in a cell, comprising: contacting a cell infected with HCV with an effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.
  • the present application provides for methods of treating a viral infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for methods of treating a viral infection in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active agent.
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active agent, whereby HCV polymerase is inhibited.
  • the present application provides for methods of treating HCV in a patient, comprising: administering to the patient a therapeutically effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and at least one additional active agent selected from the group consisting of interferons, ribavirin analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV, or mixtures thereof.
  • the present application provides for the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for treating a viral infection, e.g., an HBV/HCV infection.
  • a viral infection e.g., an HBV/HCV infection.
  • the present application provides a method for treating or preventing a viral infection comprising co-administering, to a patient in need thereof, a therapeutically effective amount of at least one compound of Formula I or II and at least one additional active agent selected from the group consisting of interferons, e.g., pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), feron, reaferon, intermax alpha, r-IFN-beta, infergen+actimmune, IFN-omega with DUROS, albuferon, locteron, Albuferon, Rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and Pegylated IFN-beta; ribavirin analogs, e.g., peg
  • the present application provides a method for antagonizing toll-like receptor 7, comprising contacting a cell having a toll-like receptor 7 with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, and/or ester thereof.
  • Example (B) The crude reaction mixture was purified by HPLC on a 50 ⁇ 21 mm C18 column (eluting 15-80% CH 3 CN in H 2 O) and lyophilized to give 1.1 mg of Example (B) as a white powder.
  • 1 H NMR 300 MHz, CD 3 OD
  • LCMS m/z for C 22 H 24 N 5 O 5 P + +H observed 470.2 at 1.62 minutes of a 3.5 minute run, eluting 5-95% CH 3 CN in H 2 O (C18 column).
  • Example (C) (28 mg, 0.68 mmol), triethylamine (114 ⁇ L, 0.82 mmol), L-Ala-OEt.HCl (21 mg, 0.14 mmol), phenol (32 mg, 0.34 mmol), aldrithiol (105 mg, 0.47 mmol) and triphenylphosphine (126 mg, 0.47 mmol) was heated at 60° C. in 1 ml of pyridine for 7 hours. The solution was concentrated and purified by HPLC to afford Example (D) (10.5 mg, 26%) as a white solid.
  • Step 2 Preparation of (2-(6-amino-2-(2-methoxyethoxy)-purin-9-yl)-ethoxymethyl)phosphonic acid diisopropyl ester (16)
  • Step 3 Preparation of (2-(6-amino-8-bromo-2-(2-methoxyethoxy)purin-9-yl)-ethoxymethyl)phosphonic acid diisopropyl ester (17)
  • Step 1 Preparation of (3-(6-amino-2-(2-methoxyethoxy)purin-9-yl)propyl)phosphonic acid diethyl ester (19)
  • Step 2 Preparation of (3-(6-amino-8-bromo-2-(2-methoxyethoxy)purin-9-yl)propyl)phosphonic acid diethyl ester (21)
  • Step 3 Preparation of (3-(6-Amino-8-hydroxy-2-(2-methoxyethoxy)purin-9-yl)propyl)phosphonic acid (Example H)
  • Step 1 Preparation of 1-(6-Amino-2-(2-methoxyethoxy)purin-9-yl)-3-phenylpropan-2-ol (22)
  • Step 2 Preparation of (2-(6-Amino-2-(2-methoxyethoxy)-purin-9-yl)-1-benzyl-ethoxymethyl)phosphonic acid diethyl ester (24)
  • Step 3 Preparation of (2-(6-Amino-8-bromo-2-(2-methoxyethoxy)purin-9-yl)-1-benzyl-ethoxymethyl)phosphonic acid diethyl ester (26)
  • Step 4 preparation of (2-(6-Amino-8-hydroxy-2-(2-methoxyethoxy)purin-9-yl)-1-benzyl-ethoxymethyl)phosphonic acid (Example I)
  • Example (I) A mixture of bromide Compound (26) prepared in Step 3 (20 mg) in 1 N HCl (1.5 ml) was stirred at 150° C. in a microwave for 12 min. The solvent was removed under vacuum and the residue was purified by prep HPLC on a C18 column (eluting a using a gradient of 5-95% CH 3 CN in H 2 O) to give Example (I).
  • Example (J) with R ⁇ H was prepared using procedures similar to those used to prepare a compound (1), except that propylene carbonate was used instead of the epoxide in Step 1.
  • Ethyl hydrogen 3-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenylphosphonate (K) (10 mg, 0.0236 mmol) was suspended in anhydrous acetonitrile (3 mL). Bromotrimethylsilane (0.2 mL) was added. After stirring at room temperature overnight, the mixture was concentrated under vacuum and treated with water (2 mL).
  • Step 1 Preparation of 1-(6-amino-2-(2-methoxyethoxy)purin-9-yl)-3-phenoxy-propan-2-ol. (31)
  • Step 2 Preparation of (2-(6-amino-2-(2-methoxyethoxy)purin-9-yl)-1-phenoxymethylethoxymethyl)-phosphonic acid diethyl ester. (32)
  • Step 3 Preparation of (2-(6-amino-8-bromo-2-(2-methoxy-ethoxy)purin-9-yl)-1-(phenoxymethyl)ethoxymethyl)phosphonic acid diethyl ester. (33)
  • Step 4 preparation of (2-(6-Amino-8-hydroxy-2-(2-methoxy-ethoxy)-purin-9-yl)-1-(phenoxymethyl)ethoxymethyl)phosphonic acid.
  • Step 1 Preparation of 2-(6-amino-2-(2-methoxyethoxy)purin-9-yl)-1-phenylethanone.
  • Step 2 2-(6-amino-2-(2-methoxyethoxy)purin-9-yl)-1-phenylethanol. (35)
  • Example O The other steps were carried out according to the procedures used in preparing Example O.
  • Example Q were prepared using procedures similar to those used to prepare Example O, except that R-2-epoxy-3-phenoxy-propane was used instead of racemic 2-epoxy-3-phenoxy-propane in step a).
  • Enantiomerically pure 2-epoxy-3-phenoxy-propane was made from chiral glycidyl tosylate according to the procedure described in Journal of Organic Chemistry, 1989, 54, 1295-1304.
  • Example R was prepared using procedures similar to those used to prepare Example O, except that S-2-epoxy-3-phenoxy-propane was used instead of racemic 2-epoxy-3-phenoxy-propane in step a).
  • Enantiomerically pure 2-epoxy-3-phenoxy-propane was made from chiral glycidyl tosylate according to the procedure described in Journal of Organic Chemistry, 1989, 54, 1295-1304.
  • Examples S and T were prepared using procedures similar to those used to prepare Example O except cis-stilbene oxide or cyclopentene oxide were used in the step 1, respectively.
  • the spectral data of the two compounds (Example S and T) and intermediates are listed below.
  • Step 1 synthesis of (6-Amino-2-(2-methoxy-ethoxy)-purin-9-yl)-phenyl-acetic acid ethyl ester (44)
  • Step 2 synthesis of 2-(6-Amino-2-(2-methoxy-ethoxy)-purin-9-yl)-2-phenylethanol (45)
  • Compound 48 was prepared by alkylating Compound 15 with the corresponding bromide, using the procedures similar to those shown in Scheme 28.
  • Example C To a solution of (3-(6-Amino-8-hydroxy-2-(2-methoxy-ethoxy)-purin-9-ylmethyl)-benzyl)-phosphonic acid (Example C) (50 mg, 0.12 mmol) in DMF, was added diisopropylethylamine (110 ⁇ l, 0.60 mmol), and chloromethyl pivalate. The reaction mixture stirred at 60° C. After checking the reaction after 6 h by LC/MS, about 60% starting material was converted to desired product. The product was isolated by prep-HPLC on a C 18 column, eluting with a gradient of 5-95% acetonitrile in water as solvent.
  • Example Z was isolated from the reaction above.
  • Examples AD, AE, and AF were prepared using procedures similar to shown in Scheme 32 except that different amino acid esters were used in the reaction.
  • Examples AI, AJ, AK, AL, AM, AN, AO, and AP were prepared from chiral phosphonic acid example Q and R using procedures similar to those used to prepare Example AC.
  • Step 1 Synthesis of (3-(6-Amino-8-mercapto-2-(2-methoxy-ethoxy)-purin-9-ylmethyl)-benzyl)-phosphonic acid monoethyl ester (51)
  • Example AS, AT, and AU were prepared from Example C using procedures as shown in Scheme 17, except that phenol was replaced with cyclic amines or oxime.
  • L-alanine isopropyl ester hydrogen chloride 80 mg, 0.48 mmol
  • triphenylphosphine 314 mg, 1.2 mmol
  • adrithiol-2 264 mg, 1.2 mmol
  • molecular sieves 50 mg
  • Example C (95 mg, 0.232 mmol) was suspended in NMP (0.5 mL). Triethylamine (0.22 mL) was added and the mixture was heated to 62° C. A solution of chloromethyl isopropyl carbonate (0.22 mL) in NMP (1.5 mL) was added with a syringe pump over 90 minutes. The mixture was heated at 62° C. for 5 more hours, and then diluted with ethyl acetate, washed with water and brine, dried with Na 2 SO 4 and evaporated under vacuum. The crude product was purified by flash chromatography on silica gel (Eluent 50% to 100% hexane/ethyl acetate) giving AV (20 mg) as colorless oil. MS: 758.2 (M+H) + .
  • Example AX was prepared using procedures similar to those used to prepare Example AW except that n-butylamine was replaced with 2-morpholinoethanamine. MS: 522.2 (M+H).
  • the crude product (Compound 55) was dissolved in chloroform (2 mL) and a 10% solution of bromine in chloroform was added dropwise until the bromine color remained. After stirring for additional 10 minutes the mixture was diluted with ethyl acetate (50 mL) and washed with 0.1N sodium thiosulfate solution, water, sodium bicarbonate solution and brine, dried with Na 2 SO 4 and evaporated under vacuum to dryness.
  • the crude product (Compound 56) was dissolved in methanol (10 mL) and 50% aqu. KOH solution (2 mL) was added. The mixture was heated under reflux until HPLC analysis showed complete disappearance of the bromide. Then the mixture was acidified with conc.
  • Examples AZ and BA were prepared using procedures similar to those as shown in Schemes 39 and 40 except that n-butylamine was replaced with benzylamine or sodium n-butoxide.
  • the crude product was dissolved in ethyl acetate and filtered through a pad of silica gel (3 g), eluting with 25% methanol in ethyl acetate. After evaporation to dryness the product was dissolved in chloroform (10 mL) and a 5% solution of bromine in chloroform was added dropwise until the bromine color remained. After stirring for additional 10 minutes the mixture was diluted with ethyl acetate (50 mL) and washed with 0.1N sodium thiosulfate solution, water, sodium bicarbonate solution and brine, dried with Na 2 SO 4 and evaporated under vacuum to dryness. The crude product was dissolved in methanol (5 mL) and 50% aqu.
  • Example BC was prepared using procedures similar to those shown in Scheme 40 expect that diethylmethylphosphonite was replaced with ethyl benzylphosphinate. MS: 467.3 (M+H).
  • 2-chloroadenine (1) (1.53 g, 9.03 mmol) was divided among three microwave vials (10-20 mL), each containing 1-butanol (10 mL) and t-BuOK (5 mL, 1M in THF). Each vial was heated to 170° C. for 40 minutes. After reaction completion the solvent was removed by rotary evaporation and the product was purified on flash column eluting 10% methanol in ethylacetate. Evaporation of solvent gave 1.33 g (70%) of 59 as an off white solid.
  • TMS-Br was added to a solution of 63 (61 mg, 0.13 mmol) in CH 3 CN was cooled to 0° C. The mixture was stirred at 0° C. for 30 minutes, then heated to 70° C. for 6.5 hours. The solvent and TMS-Br were removed by rotary evaporation, and the resulting product was purified by prep. HPLC giving 1.6 mg of BD as a white solid.
  • 2-chloroadenine (1) (1.60 g, 9.44 mmol) was divided among three microwave vials (10-20 mL), each containing Butylamine (4 mL), 1-Butanol (10 mL,), and DMSO (1 mL). Each vial was heated to 170° C. for 90 minutes. After reaction completion the solvent was removed by rotary evaporation and the product was purified on flash column eluting 10% methanol in ethylacetate. Evaporation of solvent gave 1.62 g (83%) of 64 as an off white solid.
  • Example BF was prepared using procedures similar to those shown in Schemes 39 and 40 except that n-butylamine was replaced with sodium n-butoxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/825,377 2006-07-07 2007-07-06 Modulators of toll-like receptor 7 Abandoned US20080008682A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/825,377 US20080008682A1 (en) 2006-07-07 2007-07-06 Modulators of toll-like receptor 7

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81949006P 2006-07-07 2006-07-07
US83285106P 2006-07-24 2006-07-24
US11/825,377 US20080008682A1 (en) 2006-07-07 2007-07-06 Modulators of toll-like receptor 7

Publications (1)

Publication Number Publication Date
US20080008682A1 true US20080008682A1 (en) 2008-01-10

Family

ID=38599366

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/825,377 Abandoned US20080008682A1 (en) 2006-07-07 2007-07-06 Modulators of toll-like receptor 7
US12/303,214 Active 2028-04-28 US8338593B2 (en) 2006-07-07 2007-07-06 Modulators of toll-like receptor 7

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/303,214 Active 2028-04-28 US8338593B2 (en) 2006-07-07 2007-07-06 Modulators of toll-like receptor 7

Country Status (14)

Country Link
US (2) US20080008682A1 (es)
EP (1) EP2038290B1 (es)
JP (1) JP5356228B2 (es)
AR (1) AR061839A1 (es)
AU (1) AU2007269557B2 (es)
CA (1) CA2656427C (es)
DK (1) DK2038290T3 (es)
ES (1) ES2437871T3 (es)
NZ (1) NZ572983A (es)
PL (1) PL2038290T3 (es)
PT (1) PT2038290E (es)
SI (1) SI2038290T1 (es)
TW (1) TWI399377B (es)
WO (1) WO2008005555A1 (es)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122391A1 (en) * 2001-11-14 2006-06-08 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20070190071A1 (en) * 2004-03-26 2007-08-16 Dainippon Sumitomo Pharma Co., Ltd. 9-Substituted 8-oxoadenine compound
US20090047249A1 (en) * 2007-06-29 2009-02-19 Micheal Graupe Modulators of toll-like receptor 7
US20090118263A1 (en) * 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
US20090131458A1 (en) * 2007-02-19 2009-05-21 Smithkline Beecham Corporation Compounds
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
US20090202484A1 (en) * 2006-07-07 2009-08-13 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2010014913A1 (en) * 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
US20100087443A1 (en) * 2007-03-19 2010-04-08 Roger Victor Bonnert 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
US20100093998A1 (en) * 2007-03-20 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100210598A1 (en) * 2009-02-11 2010-08-19 Regents Of The University Of California, San Diego Toll-like receptor modulators and treatment of diseases
US20100240623A1 (en) * 2006-07-05 2010-09-23 Anthony Cook 8-oxoadenine derivatives acting as modulators of tlr7
US20100280001A1 (en) * 2007-05-08 2010-11-04 Roger Victor Bonnert Imidazoquinolines with immuno-modulating properties
WO2010151472A1 (en) * 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US20110092485A1 (en) * 2009-08-18 2011-04-21 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110098294A1 (en) * 2006-05-31 2011-04-28 Carson Dennis A Purine analogs
US20110098248A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110118235A1 (en) * 2009-08-18 2011-05-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110136801A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co. Ltd. Novel Compounds
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US8067413B2 (en) * 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
US8067426B2 (en) * 2008-08-11 2011-11-29 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US8067411B2 (en) * 2006-12-14 2011-11-29 Astrazeneca Ab Compounds
US8314090B2 (en) 2008-11-06 2012-11-20 Ventirx Pharmaceuticals, Inc. Methods of synthesis of benzazepine derivatives
EP2461690A4 (en) * 2009-08-07 2013-03-27 Glaxosmithkline Biolog Sa LIPIDED OXOADENINE DERIVATIVES
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
US20130274465A1 (en) * 2010-09-01 2013-10-17 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
US8673907B2 (en) 2007-12-17 2014-03-18 Astrazeneca Ab Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
US8907108B2 (en) 2012-10-26 2014-12-09 Industrial Technology Research Institute P-type organic semiconductor material and optoelectronic device utilizing the same
US9045472B2 (en) 2010-12-16 2015-06-02 Astrazeneca Ab Imidazoquinoline compounds
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
US9540383B2 (en) 2012-11-20 2017-01-10 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9555036B2 (en) 2012-08-24 2017-01-31 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10112946B2 (en) 2011-07-22 2018-10-30 Glaxosmithkline Llc Composition
US10202384B2 (en) 2014-09-16 2019-02-12 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10414768B2 (en) * 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US10603369B2 (en) 2011-03-02 2020-03-31 Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and/or adjuvant
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12029744B2 (en) 2019-04-12 2024-07-09 Riboscience Llc Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
UY32720A (es) * 2009-06-23 2011-01-31 Gilead Sciences Inc Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
WO2010151487A1 (en) * 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of telaprevir with 5- ({6- [2,4-bis (trifluoromethyl) phenyl] pyridazin-3 -yl)methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c]pyridine for the treatment of hcv
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
RU2014112343A (ru) 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
ES2746859T3 (es) * 2014-04-11 2020-03-09 Gilead Sciences Inc Métodos para la preparación de análogos de nucleótidos antivirales
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP2015509520A (ja) 2012-03-07 2015-03-30 ノバルティス アーゲー 狂犬病ウイルス免疫原のアジュバント化製剤
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CN107312039B (zh) * 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
MX377789B (es) 2012-10-08 2025-03-10 Dow Global Technologies Llc Compuestos de organofosforo para espumas de poliuretano retardantes de llama.
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
KR102297357B1 (ko) 2014-03-26 2021-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
CN105518012B (zh) * 2014-06-25 2018-03-02 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
EP3939985B1 (en) 2014-12-26 2024-05-08 Emory University Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016193405A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
WO2017027434A1 (en) * 2015-08-10 2017-02-16 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
FI3526323T3 (fi) 2016-10-14 2023-06-06 Prec Biosciences Inc Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
WO2018119013A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
MX2019007262A (es) 2016-12-22 2019-09-05 Merck Sharp & Dohme Compuestos antivirales de bencilamina fosfodiamida.
AU2017378959B2 (en) 2016-12-23 2021-09-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
CN108948016B (zh) * 2017-05-19 2021-02-26 江苏恒瑞医药股份有限公司 嘌呤酮类衍生物、其制备方法及其在医药上的应用
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
JP2021528363A (ja) 2018-06-12 2021-10-21 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CR20210215A (es) 2018-10-31 2021-06-17 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102808642B1 (ko) 2019-03-07 2025-05-14 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
SI4037708T1 (sl) 2019-09-30 2025-01-31 Gilead Sciences, Inc. Cepiva proti hbv in postopki zdravljenja hbv
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN111643661A (zh) * 2020-06-08 2020-09-11 王竹林 新型免疫佐剂、化合物及其应用
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
TW202412816A (zh) 2022-06-10 2024-04-01 美商弗沃德醫療公司 ＴＮＦ—α活性調節劑
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
CN119080839B (zh) * 2024-11-07 2025-03-11 上海柯君医药科技有限公司 一种抗病毒药物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994321A (en) * 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
NZ548771A (en) * 2003-12-30 2010-05-28 Gilead Sciences Inc Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
TWI399377B (zh) * 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體７之調節劑
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994321A (en) * 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20060122391A1 (en) * 2001-11-14 2006-06-08 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US8969362B2 (en) 2004-03-26 2015-03-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
US8012964B2 (en) * 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
US20110306610A1 (en) * 2004-03-26 2011-12-15 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
US8575180B2 (en) * 2004-03-26 2013-11-05 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
US20070190071A1 (en) * 2004-03-26 2007-08-16 Dainippon Sumitomo Pharma Co., Ltd. 9-Substituted 8-oxoadenine compound
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US20090118263A1 (en) * 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
US20110098294A1 (en) * 2006-05-31 2011-04-28 Carson Dennis A Purine analogs
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US20100240623A1 (en) * 2006-07-05 2010-09-23 Anthony Cook 8-oxoadenine derivatives acting as modulators of tlr7
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US20090202484A1 (en) * 2006-07-07 2009-08-13 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US8067411B2 (en) * 2006-12-14 2011-11-29 Astrazeneca Ab Compounds
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US20100120799A1 (en) * 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
US7977344B2 (en) * 2007-02-19 2011-07-12 Glaxosmithkline Llc Compounds
US20090131458A1 (en) * 2007-02-19 2009-05-21 Smithkline Beecham Corporation Compounds
US20100087443A1 (en) * 2007-03-19 2010-04-08 Roger Victor Bonnert 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
US8067413B2 (en) * 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
US8063051B2 (en) * 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
US20110028715A1 (en) * 2007-03-20 2011-02-03 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US20100093998A1 (en) * 2007-03-20 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US20100280001A1 (en) * 2007-05-08 2010-11-04 Roger Victor Bonnert Imidazoquinolines with immuno-modulating properties
US8436178B2 (en) 2007-05-08 2013-05-07 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
US8993755B2 (en) 2007-06-29 2015-03-31 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US9611268B2 (en) 2007-06-29 2017-04-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7968544B2 (en) * 2007-06-29 2011-06-28 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US20110236348A1 (en) * 2007-06-29 2011-09-29 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US20090047249A1 (en) * 2007-06-29 2009-02-19 Micheal Graupe Modulators of toll-like receptor 7
US8673907B2 (en) 2007-12-17 2014-03-18 Astrazeneca Ab Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
WO2010014913A1 (en) * 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
US20100029585A1 (en) * 2008-08-01 2010-02-04 Howbert J Jeffry Toll-like receptor agonist formulations and their use
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
US9216192B2 (en) 2008-08-01 2015-12-22 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
US9877968B2 (en) 2008-08-11 2018-01-30 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US9233962B2 (en) 2008-08-11 2016-01-12 Glaxosmithkline Llc Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US8067426B2 (en) * 2008-08-11 2011-11-29 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US9346806B2 (en) 2008-08-11 2016-05-24 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US10117873B2 (en) 2008-08-11 2018-11-06 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US8314090B2 (en) 2008-11-06 2012-11-20 Ventirx Pharmaceuticals, Inc. Methods of synthesis of benzazepine derivatives
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US11110091B2 (en) 2008-12-09 2021-09-07 Gilead Sciences, Inc. Modulators of toll-like receptors
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US20100210598A1 (en) * 2009-02-11 2010-08-19 Regents Of The University Of California, San Diego Toll-like receptor modulators and treatment of diseases
US8729088B2 (en) 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
WO2010151472A1 (en) * 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
EP2461690A4 (en) * 2009-08-07 2013-03-27 Glaxosmithkline Biolog Sa LIPIDED OXOADENINE DERIVATIVES
US9044481B2 (en) 2009-08-07 2015-06-02 Glaxosmithkline Biologicals S.A. Lipidated oxoadenine derivatives
EP3199159A1 (en) * 2009-08-07 2017-08-02 GlaxoSmithKline Biologicals S.A. Lipidated oxoadenine derivatives
US8524702B2 (en) 2009-08-18 2013-09-03 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110092485A1 (en) * 2009-08-18 2011-04-21 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US9242964B2 (en) 2009-08-18 2016-01-26 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US20110118235A1 (en) * 2009-08-18 2011-05-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US9655904B2 (en) 2009-08-18 2017-05-23 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US9126940B2 (en) 2009-08-18 2015-09-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US9161934B2 (en) 2009-10-22 2015-10-20 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110098248A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US20110136801A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co. Ltd. Novel Compounds
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US9173936B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US9180183B2 (en) 2010-04-30 2015-11-10 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US10098949B2 (en) 2010-09-01 2018-10-16 Glaxosmithkline Biologicals S.A. Adsorption of immunopotentiators to insoluble metal salts
US9315530B2 (en) * 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
US20130274465A1 (en) * 2010-09-01 2013-10-17 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
US9346848B2 (en) 2010-09-22 2016-05-24 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US9045472B2 (en) 2010-12-16 2015-06-02 Astrazeneca Ab Imidazoquinoline compounds
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
US9452154B2 (en) 2010-12-20 2016-09-27 Gilead Sciences, Inc. Methods for treating HCV
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
US10603369B2 (en) 2011-03-02 2020-03-31 Glaxosmithkline Biologicals Sa Combination vaccines with lower doses of antigen and/or adjuvant
US10112946B2 (en) 2011-07-22 2018-10-30 Glaxosmithkline Llc Composition
US10456414B2 (en) 2011-09-16 2019-10-29 Gilead Pharmasset Llc Methods for treating HCV
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9931399B2 (en) 2012-03-08 2018-04-03 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US10842868B2 (en) 2012-03-08 2020-11-24 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US9662336B2 (en) 2012-08-24 2017-05-30 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US10022442B2 (en) 2012-08-24 2018-07-17 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9555036B2 (en) 2012-08-24 2017-01-31 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US8907108B2 (en) 2012-10-26 2014-12-09 Industrial Technology Research Institute P-type organic semiconductor material and optoelectronic device utilizing the same
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9540383B2 (en) 2012-11-20 2017-01-10 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9907847B2 (en) 2012-11-20 2018-03-06 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US10202384B2 (en) 2014-09-16 2019-02-12 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11072615B2 (en) 2014-09-16 2021-07-27 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10508117B2 (en) 2014-09-16 2019-12-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US12486271B2 (en) 2014-09-16 2025-12-02 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11773098B2 (en) 2014-09-16 2023-10-03 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10414768B2 (en) * 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12029744B2 (en) 2019-04-12 2024-07-09 Riboscience Llc Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
US12275717B2 (en) 2020-05-06 2025-04-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Also Published As

Publication number Publication date
US8338593B2 (en) 2012-12-25
DK2038290T3 (da) 2013-12-02
US20090202484A1 (en) 2009-08-13
PL2038290T3 (pl) 2014-03-31
CA2656427C (en) 2014-12-09
JP2009542697A (ja) 2009-12-03
HK1126222A1 (en) 2009-08-28
CA2656427A1 (en) 2008-01-10
EP2038290B1 (en) 2013-09-04
TWI399377B (zh) 2013-06-21
AU2007269557A1 (en) 2008-01-10
TW200813057A (en) 2008-03-16
JP5356228B2 (ja) 2013-12-04
AR061839A1 (es) 2008-09-24
SI2038290T1 (sl) 2014-01-31
ES2437871T3 (es) 2014-01-14
PT2038290E (pt) 2013-12-10
WO2008005555A1 (en) 2008-01-10
NZ572983A (en) 2011-06-30
AU2007269557B2 (en) 2013-11-07
EP2038290A1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
US8338593B2 (en) Modulators of toll-like receptor 7
US9611268B2 (en) Modulators of toll-like receptor 7
US11344555B2 (en) Nucleotide analogs
CA2745295C (en) Modulators of toll-like receptors
CN102348713B (zh) 用于抗病毒治疗的carba-核苷类似物
US8884011B2 (en) Nucleotide analogues as precursor molecules for antivirals
HK1126222B (en) Modulators of toll-like receptor 7

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHONG, LEE S.;DESAI, MANOJ C.;GALLAGHER, BRIAN;AND OTHERS;REEL/FRAME:019822/0140;SIGNING DATES FROM 20070904 TO 20070910

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION